Eli Lilly's Jaypirca Receives Positive EU Regulatory Opinion for CLL

What happened

Eli Lilly announced that the CHMP issued a positive opinion for Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for treating adults with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment. The opinion is based on data from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials. BRUIN CLL-313 was the first Phase 3 study to evaluate a non-covalent BTK inhibitor exclusively in treatment-naïve CLL patients, while BRUIN CLL-314 was the first Phase 3 trial to compare non-covalent and covalent BTK inhibitors in the treatment-naïve setting. Results from both studies were presented at the 2025 American Society of Hematology Annual Meeting and published in The Journal of Clinical Oncology. Following the positive opinion, the application has been referred to the European Commission for final marketing authorization, with a decision expected within one to two months.

Why it matters

This positive opinion moves Lilly closer to expanding Jaypirca's approved indications in the European Union, potentially making it available to CLL patients at any stage of treatment. The trials demonstrated strong efficacy and tolerability, positioning Jaypirca as a versatile treatment option in a disease where therapy sequencing is critical. Because many CLL patients may receive fewer lines of therapy over their lifetime due to improved contemporary treatments, early-line treatment choices carry significant long-term importance. If approved by the European Commission, Jaypirca would be available to newly diagnosed patients, those previously treated, and those who have or have not received prior BTK inhibitors, broadening the drug's commercial reach and patient impact in the EU market.

Bigger picture

BTK inhibitors have become a cornerstone of CLL treatment, but most approved options are covalent inhibitors. Jaypirca is a non-covalent BTK inhibitor, offering a differentiated mechanism that may provide benefits in tolerability and efficacy across patient populations. The BRUIN CLL-313 and CLL-314 trials represent the first head-to-head comparisons of non-covalent and covalent BTK inhibitors in treatment-naïve CLL, filling a key evidence gap in the field. As the competitive landscape in CLL evolves, Lilly is positioning Jaypirca to capture share across all therapy lines. The company has also submitted trial data to the US Food and Drug Administration, with a regulatory decision expected in the second half of 2026, indicating a coordinated global expansion strategy.

What to watch

Investors should monitor the European Commission's final decision, expected within one to two months, which will determine whether Jaypirca gains expanded approval across the EU. Additionally, watch for the FDA decision in the second half of 2026, which could unlock a larger US market opportunity. Longer-term, keep an eye on real-world uptake data and any updates on head-to-head efficacy versus competing BTK inhibitors, as well as Lilly's broader oncology pipeline developments.